ClinicalTrials.gg
RecruitingNCT05294302Updated Nov 20, 2026

Testing eSCCIP: An eHealth Psychosocial Intervention for English and Spanish Speaking Parents of Children With Cancer

An interventional study of eSCCIP/eSCCIP-SP and Coping Space in Pediatric Cancer, sponsored by Nemours Children's Clinic. Recruiting at 3 sites in United States. Per ClinicalTrials.gov, last updated 2026-11-20.

Sponsored by Nemours Children's Clinic · Not applicable, Interventional, and Supportive care

How we know

From the registry’s dates

  • Started Apr 2023; still recruiting 3 years 7 months later.
Updated Nov 20, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
350
Allocation
Randomized
Sex
All
01

Study summary

It is critical to provide accessible evidence-based psychosocial support to parents and caregivers of children with cancer (PCCC) in order to mitigate individual and family-level psychosocial risks. This effectiveness trial evaluates an eHealth intervention for English- and Spanish-speaking (PCCC) with study endpoints focused on decreasing negative psychosocial sequelae (acute distress, posttraumatic stress, and anxiety) and improving coping abilities (coping self-efficacy, cognitive coping strategies). The long-term goal of this research program is to sustain and disseminate an effective, scalable, high-reach, and cost-effective intervention to provide crucial support to PCCC across the pediatric cancer trajectory.

Read the detailed description

The psychosocial needs and risks of children with cancer and their families are well-documented in the literature, including the increased risk of parental distress, posttraumatic stress, and anxiety. There is a critical need to provide evidence-based psychosocial care to parents and caregivers of children with cancer (PCCC), although many challenges exist regarding in-person intervention delivery. eHealth interventions represent an exciting potential opportunity to address many of the barriers to in-person intervention delivery in this population, but are not yet widely utilized in pediatric psychosocial cancer care. The COVID-19 pandemic has further illuminated the need for flexible, acceptable, and accessible eHealth psychosocial interventions.

The Electronic Surviving Cancer Competently Intervention Program (eSCCIP) is an innovative eHealth intervention for PCCC, delivered through a combination of self-guided interactive online content and telehealth follow-up with a therapist. eSCCIP aims to decrease symptoms of acute distress, anxiety, and posttraumatic stress while improving coping abilities by delivering evidence-based therapeutic content through a flexible, easily accessible eHealth tool. The intervention is delivered to one or two PCCC per family, but content is designed to apply to the whole family system. eSCCIP is grounded in principles of cognitive-behavioral and family systems therapy and is adapted from two efficacious in-person interventions for caregivers of children with cancer, the Surviving Cancer Competently Intervention Program (SCCIP) and the Surviving Cancer Competently Intervention Program - Newly Diagnosed (SCCIP-ND). eSSCIP has been rigorously developed through a stakeholder-engaged development process involving close collaboration with PCCC, content experts in pediatric oncology and eHealth, and web design and development experts. A Spanish language adaptation of eSCCIP, El Programa Electronico de Intervencion para Superar Cancer Competentemente (eSCCIP-SP), has recently been developed following a rigorous process and is now ready for testing as well. The self-guided online modules of eSCCIP/eSCCIP-SP feature a mix of didactic video content, novel multifamily video discussion groups featuring parents of children with cancer, and hands-on interactive activities. P

The objective of the proposed study is to test eSCCIP/eSCCIP-SP in a rigorous, multisite RCT compared to an education control condition. The primary study endpoint is a reduction in acute distress from baseline to post-intervention, with secondary endpoints focused on reductions in symptoms of posttraumatic stress and anxiety ,and improvements in coping self-efficacy and cognitive coping. Data will be collected at three timepoints (baseline, post-intervention, and three-month follow-up). An additional, exploratory aim will be focused on implementation strategies and potential costs and cost-savings of eSCCIP/eSCCIP-SP, laying the groundwork for future trials focused on dissemination and implementation, stepped-care models, and intervention refinement.

02

Conditions studied

  • Pediatric Cancer

Browse trials for

Keywords

  • eHealth
  • pediatric cancer
  • parents
  • psychosocial intervention
03

In context

Neoplasms

10,838 studies on the registry are indexed under Neoplasms; 2,322 are open to participants now.

This study's planned enrollment of 350 is above the median of 60 across 7,716 interventional studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

Nemours Children's Clinic is the lead sponsor of 130 studies on the registry; 26 are open to participants now.

Of its 9 completed or terminated interventional studies of FDA-regulated products, 6 (67%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants must be the parent or primary caregiver of a child (ages 0 - 18 years old) diagnosed with cancer.
  • Participants must be able to speak and read English or Spanish.
  • Participants must have access to the internet through a computer or mobile device (e.g., smartphone, tablet).

Exclusion criteria

Exclusion Criteria:

  • PCCC are ineligible to participate if their child is not expected to live longer than six months from the time of potential recruitment
05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
350 participants (estimated)

Study arms

  • Active comparator
    eSCCIP/eSCCIP-SP

    The Electronic Surviving Cancer Competently Intervention Program (eSCCIP) is an innovative eHealth intervention that combines cognitive behavioral and family systems therapy to provide parents and caregivers of children with cancer (PCCC) with evidence-based coping skills and psychosocial support focused on the family unit. eSCCIP has three 30-minute, self-directed, online modules which feature a unique mix of original video content and interactive activities, supplemented by three telehealth follow-up sessions. A stakeholder-informed Spanish-language adaption of eSCCIP (eSCCIP-SP) has been developed and will be offered to Spanish-speaking PCCC. eSCCIP aims to reduce acute distress and symptoms of post-traumatic stress while increasing positive coping self-appraisal and use of cognitive coping skills.

    Behavioral: eSCCIP/eSCCIP-SP

  • Active comparator
    Coping Space

    PCCC randomized to the patient education control condition will be given access to a website with information about psychosocial functioning, coping, and PTSS related to pediatric cancer. This website will be hosted on the same platform as the intervention, available in English and Spanish, and will consist of information modified from CopingSpace.org. CopingSpace.org is an evidence-informed website developed by Ryan's Case for Smiles, a national organization dedicated to supporting families impacted by pediatric cancer and other chronic diseases.

    Behavioral: Coping Space

Interventions

  • BehavioraleSCCIP/eSCCIP-SP

    eSCCIP/eSCCIP-SP is a psychosocial eHealth intervention for PCCC. It consists of four self-guided, web-based modules (including an introductory module) and three telehealth sessions with a study interventionist.

  • BehavioralCoping Space

    Coping Space is a psychosocial informational website for PCCC.

06

What researchers measure

Primary outcomes

  1. K-6

    Questionnaire to measure acute distress.

    Time frame: Up to 20 weeks

Secondary outcomes

  1. Multidimensional Scale of Perceived Social Support

    Questionnaire to measure perceived social support from family, friends, and significant other.

    Time frame: Up to 20 weeks

  2. The COVID-19 Exposure and Family Impact Scale (CEFIS)

    The CEFIS assesses the extent to which a family has experienced or been "exposed" to COVID-19 related potentially traumatic events (e.g., economic changes, illness in family) and the impact of these events on the family's functioning and wellbeing.

    Time frame: Up to 20 weeks

  3. Coping Self-Efficacy Scale

    Questionnaire to measure perceived ability to cope effectively with challenging situations across three domains (use problem-focused coping, stop unpleasant emotions and thoughts, get support from friends and family).

    Time frame: Up to 20 weeks

  4. Cognitive Emotion Regulation Questionnaire

    Questionnaire to identify cognitive coping strategies used after a negative event or situation. Measures nine different cognitive coping strategies.

    Time frame: Up to 20 weeks

  5. Distress Thermometer

    Single-item indicator of psychosocial distress that is widely used in the oncology.

    Time frame: Up to 20 weeks

  6. PROMIS Short Form v1.0 - Anxiety - 8a

    Questionnaire measuring symptoms of anxiety.

    Time frame: Up to 20 weeks

  7. PCL-5

    Questionnaire to assess for symptoms of PTSD in civilian population.

    Time frame: Up to 20 weeks

07

Study locations

1 of 3 sites recruiting
08

References and documents

Publications

  • Canter KS, Ritterband L, Freyer DR, Askins MA, Bava L, Loucas C, Arasteh K, You W, Kazak AE. The Electronic Surviving Cancer Competently Intervention Program-a Psychosocial Digital Health Intervention for English- and Spanish-Speaking Parents of Children With Cancer: Protocol for Randomized Controlled Trial. JMIR Res Protoc. 2023 Jun 2;12:e46339. doi: 10.2196/46339. PubMed 37267038 ↗

Individual participant data

Plan to share: No — No plan to share individual participant data; de-identified group data may be available to qualified researchers upon request to the principal investigator.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2023 (actual). Primary completion is estimated for Jan 2027, 45 months after the start.

Of 1,993 non-industry interventional studies with no phase under Neoplasms, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 52. This study's planned 45 months is above that.

Counting every sponsor, half of 2,068 studies reached it within 29 months; a quarter within 13 and three quarters within 52.

Neoplasms covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 20, 2026: primary completion Dec 2026 → Jan 2027 and completion Dec 2026 → Jan 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Feb 21, 2022
First posted
Mar 24, 2022
StartActual
Apr 14, 2023
Primary completionEst.
Jan 31, 2027was Dec 2026
CompletionEst.
Jan 31, 2027was Dec 2026
Last update
Nov 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Dec 31, 2026→Jan 31, 2027
Nov 20, 2026
Study completion
Dec 31, 2026→Jan 31, 2027
Nov 20, 2026
Show all 1 update
  1. Nov 20, 2026
    Primary completion Dec 31, 2026→Jan 31, 2027
    Study completion Dec 31, 2026→Jan 31, 2027
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05294302
Responsible party
Kimberly Canter (Senior Research Scientist, Nemours Children's Clinic) — Principal investigator
First posted
Mar 24, 2022
Start date
Apr 14, 2023
Primary completion
Jan 31, 2027 (estimated)
Completion
Jan 31, 2027 (estimated)
Last update
Nov 20, 2026

Study contacts

Kimberly Canter, Ph.D.
Contact
kimberly.canter@nemours.org
3026514501

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion